Making the Connection: A Call to Action Against Undiagnosed Atrial Fibrillation

Improving Detection — Reducing Risk

Click Here to View Course Listing

ACTIVITY DESCRIPTION/STATEMENT OF NEED

In this activity, an expert in cardiology discusses best practices for the screening, diagnosis, and treatment of atrial fibrillation to reduce thromboembolic risk.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of family medicine physicians, internal medicine physicians, cardiologists, nurse practitioners, physician assistants, nurses, pharmacists, and other clinicians involved in the recognition and treatment of patients with atrial fibrillation.

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

  • Recognize the prevalence of undiagnosed atrial fibrillation (AF) in patients 65 years and older at risk for AF and stroke
  • Discuss the need for opportunistic and systematic screening for AF among individuals 65 years of age and older and at high risk for AF and stroke
  • Employ various screening methods routinely in clinical practice to ensure that patients at risk for AF and stroke are diagnosed
  • Apply guideline recommendations as well as safety, efficacy, and real-world data on non–vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic risk reduction in patients with AF

ACCREDITATION

Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Florida College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education: Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Successful completion of this continuing nursing education activity will be awarded 1.0 contact hour(s).

Continuing Pharmacy Education: The Medical Learning Institute, Inc. (MLI) designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: 0468-9999-20-006-H01-P

Type of Activity: Knowledge

PROVIDERSHIP

This CME activity is jointly provided by University of Florida College of Medicine and PVI, PeerView Institute for Medical Education.

This activity has been developed in collaboration with the North American Thrombosis Forum.

SUPPORT

This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.

RELEASE AND EXPIRATION DATES: March 27, 2020 – March 26, 2021

AGENDA

  • The Prevalence of Undetected Nonvalvular Atrial Fibrillation in At-Risk Patients
  • Consequences of NVAF and the Importance of Screening At-Risk Populations
  • Screening Strategies for NVAF and Subsequent Treatment for Diagnosed Patients

FACULTY DISCLOSURES AND COI

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Chair
Christian T. Ruff, MD, MPH
Director of General Cardiology
Brigham and Women’s Hospital
Investigator and Director of Genetics Core Laboratory 
TIMI Study Group
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts
 
Christian T. Ruff, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Anthos Therapeutics; Bayer HealthCare Pharmaceuticals, Inc; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; MedImmune, Inc.; Pfizer; and Portola Pharmaceuticals, Inc.
Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; MedImmune, Inc.; and National Institutes of Health (Research Support to Institution).

CME Reviewer
Ramil Goel, MD
 
Planning Committee Disclosures
Tracy L. Greene, MSN, RN, FNP-C, Nurse Planner, MLI, has nothing to disclose.
Teresa Haile, RPh, MBA, Pharmacy Planner, MLI, has nothing to disclose.
 
The planners from Medical Learning Institute, Inc., the CNE/CPE accredited provider, the North American Thrombosis Forum, and PeerView Institute for Medical Education, joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.
Margery Tamas, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant for Fresenius Medical Care North America.

Content/Peer Reviewer Disclosures
The following Content/Peer Reviewers have nothing to disclose:
Nancy Nesser, JD, PharmD
Bobbie Perrin, FNP-C, OCN

Generic Disclosure Statement

The information provided at this CME/CNE/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

INSTRUCTIONS FOR ACTIVITY COMPLETION

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 80% or higher is needed to obtain CME credit and 70% or higher to obtain CNE/CPE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For Pharmacists: Upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: mycpemonitor.net.